Found 92 results in Expert Content

Summary: ​Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Summary: Catalent CEO Johh Chiminski discusses how the pandemic has made us question how the future of pharma manufacturing will be altered post Covid-19.

Summary: In this webinar, Catalent experts will explain how the phase appropriate expertise and technologies of the OneXpress® Solution can help streamline development and manufacturing, speed up your program timelines and reduce risks to transform your science into a successful treatment.

Summary: Phase-appropriate CMC-related activities can facilitate the transition from early development through commercialization.

Summary: Drug development requires integrating multi-disciplinary business, regulatory and scientific activities. To successfully support a client’s program, it is imperative to provide advice and services that support all three in the context of a program’s goal. In this exclusive webinar presented by Jim Spavins...

Summary: The transition from early phase to late phase of a small molecule program plays a pivotal role in determining a program’s ultimate success. Early planning strategies can help minimize the burdens often faced in that transition. The implementation of modeling tools...

This article discusses why roller compaction is a robust option when developing a tablet or capsule formulation.

Summary: Recorded at Manufacturing Chemist Live 2020, this presentation discusses some of the key issues to consider when planning for the scale-up of a small molecule development program.

Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.

Summary: Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, recently sat down for an interview...